Oric Pharmaceuticals Inc (ORIC) Stock Price, Quote & News

Company Profile

ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies to counter the resistance mechanisms cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, that selectively target epidermal growth factor receptor (EGFR) exon 20 and human epidermal growth factor receptor 2 exon 20 with high potency towards exon 2...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 388 5600

Website: www.oricpharma.com

Address:

240 East Grand Avenue, 2nd Floor, South San Francisco, United States

CH_Expat Dec. 18 at 8:28 PM

$ORIC Interesting bloodbath here. At COGT I made a mistake and thought there were "reasons" when it traded at 200m EV. So worth watching.

1 · Reply

UgoGreg Dec. 17 at 6:38 AM

$ORIC https://youtu.be/ygBN8MilTyc

0 · Reply

McMillion1 Dec. 11 at 2:57 AM

$FDMT $GOSS $ORIC

0 · Reply

McMillion1 Dec. 10 at 12:36 PM

$ORIC $GOSS $FDMT - 12 to 24 months

0 · Reply

CH_Expat Dec. 8 at 5:17 PM

$ORIC What do you think of it at this levels?

1 · Reply

JarvisFlow Dec. 8 at 2:50 PM

Wells Fargo updates rating for ORIC Pharmaceuticals ( $ORIC ) to Overweight, target set at 19 → 25.

0 · Reply

JarvisFlow Dec. 8 at 2:39 PM

Wedbush updates rating for ORIC Pharmaceuticals ( $ORIC ) to Outperform, target set at 20.

0 · Reply

AlertsAndNews Dec. 6 at 9:49 PM

$ORIC Highly differentiated 1L preliminary systemic activity of 67% ORR and 100% intracranial ORR (by BICR-RANO), including in patients with active brain metastases "Highly differentiated 1L preliminary systemic activity of 67% ORR and 100% intracranial ORR (by BICR-RANO), including in patients with active brain metastases Company to host a conference call and webcast on Saturday, December 6, 2025, at 8:00 pm ET"

0 · Reply

OpenOutcrier Dec. 5 at 1:42 PM

$ORIC (+1.6% pre) ORIC Pharmaceuticals reports 35% response rate for lung cancer drug https://ooc.bz/l/86421

0 · Reply

Trader1141 Dec. 5 at 12:09 PM

$ORIC Short Float over 30%…. If it starts moving 😍

0 · Reply

ORIC Pharmaceuticals, Inc. (ORIC) Discusses Enozertinib Phase Ib Results and Differentiation in EGFR-Mutated Non-Small Cell Lung Cancer Transcript

Dec 5, 2025, 8:00 PM EST - 19 days ago

ORIC® Pharmaceuticals Presents Potential Best-in-Class Profile for Enozertinib with Robust Systemic and CNS Activity in 1L and 2L NSCLC Patients with EGFR Exon 20 Mutations at the ESMO Asia Congress 2025

Dec 5, 2025, 4:30 PM EST - 19 days ago

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Dec 5, 2025, 1:00 AM EST - 20 days ago

ORIC® Pharmaceuticals Presents Enozertinib Data in NSCLC Patients with HER2 Exon 20 Mutations at the ESMO Asia Congress 2025

Dec 4, 2025, 9:45 PM EST - 20 days ago

ORIC® Pharmaceuticals Presents Potential Best-in-Class Profile for Enozertinib with Robust Systemic and CNS Activity in 1L and Previously Treated NSCLC Patients with EGFR Atypical Mutations at the ESMO Asia Congress 2025

Dec 3, 2025, 4:01 PM EST - 21 days ago

ORIC® Pharmaceuticals Announces Enozertinib (ORIC-114) Late-Breaking Oral Presentations in EGFR Atypical and EGFR exon 20 NSCLC at the ESMO Asia Congress 2025

Dec 3, 2025, 6:45 AM EST - 22 days ago

Top 3 Health Care Stocks That May Rocket Higher In December

LRMR PRGO

Dec 1, 2025, 8:00 AM EST - 24 days ago

ORIC® Pharmaceuticals Announces Enozertinib (ORIC-114) Poster Presentation in HER2 exon 20 NSCLC at the ESMO Asia Congress 2025

Nov 24, 2025, 4:05 PM EST - 4 weeks ago

ORIC® Pharmaceuticals to Participate in the 8th Annual Evercore Healthcare Conference

Nov 13, 2025, 4:10 PM EST - 5 weeks ago

ORIC® Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Clinical and Operational Updates

Nov 13, 2025, 4:05 PM EST - 5 weeks ago

ORIC® Pharmaceuticals Announces Completion of Dose Exploration Portion of ORIC-944 Phase 1b Clinical Trial and Continues to Demonstrate Potential Best-in-Class Efficacy and Safety

Nov 6, 2025, 4:00 PM EST - 6 weeks ago

ORIC® Pharmaceuticals Announces Publication in Cancer Research on the Discovery and Development of Enozertinib, a Highly Selective, Brain-Penetrant EGFR Inhibitor

Nov 4, 2025, 4:30 PM EST - 7 weeks ago

ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences

Oct 27, 2025, 8:30 AM EDT - 2 months ago

ORIC® Pharmaceuticals Presented Preclinical Data at the EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics Supporting Best-in-Class Potential of ORIC-944 to Treat Patients With Prostate Cancer and Other Solid Tumors

Sep 3, 2025, 7:37 PM EDT - 4 months ago

ORIC Pharmaceuticals, Inc. (ORIC) Pharmaceuticals, Inc. Presents At Citi's Biopharma Back To School Conference Transcript

Aug 18, 2025, 4:05 PM EDT - 4 months ago

ORIC® Pharmaceuticals Expands Leadership Team with the Appointment of Kevin Brodbeck as Chief Technical Officer

Aug 12, 2025, 4:05 PM EDT - 4 months ago

ORIC® Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operational Updates

May 29, 2025, 11:15 AM EDT - 7 months ago

ORIC Pharmaceuticals Touts Positive Efficacy, Safety Data From Early-Stage Prostate Cancer Candidate, Raises Capital

May 28, 2025, 4:05 PM EDT - 7 months ago

ORIC® Pharmaceuticals Announces $125 Million Private Placement Financing

May 28, 2025, 4:05 PM EDT - 7 months ago

ORIC® Pharmaceuticals Announces Potentially Best-In-Class Preliminary Efficacy and Safety Data from Ongoing Phase 1b Trial of ORIC-944 in Combination with AR Inhibitors for the Treatment of Patients with mCRPC

May 27, 2025, 8:00 AM EDT - 7 months ago

ORIC® Pharmaceuticals to Present Initial Data from Phase 1b Trial of ORIC-944 in Combination with Androgen Receptor Inhibitors in Patients with mCRPC

May 5, 2025, 4:05 PM EDT - 8 months ago

ORIC® Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Updates

Apr 28, 2025, 4:30 PM EDT - 8 months ago

ORIC® Pharmaceuticals Presents Preclinical Data to Support the Potential of ORIC-944 as a Best-in-Class PRC2 Inhibitor for the Treatment of Prostate Cancer at the 2025 American Association for Cancer Research (AACR) Annual Meeting

Apr 22, 2025, 9:15 AM EDT - 8 months ago

ORIC Pharmaceuticals: Multiple Data Releases In 2025 Make It A Must-Watch Biotech

Mar 25, 2025, 4:30 PM EDT - 9 months ago

ORIC® Pharmaceuticals Announces ORIC-944 Preclinical Presentation at the 2025 American Association for Cancer Research (AACR) Annual Meeting

Feb 25, 2025, 4:15 PM EST - 10 months ago

ORIC® Pharmaceuticals Announces Focused Registrational Clinical Development Plans for Lead Programs, Extended Cash Runway, and Updated Corporate Milestones

Feb 18, 2025, 4:05 PM EST - 11 months ago

ORIC® Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Updates

Jan 13, 2025, 8:05 AM EST - 1 year ago

ORIC® Pharmaceuticals Provides Early Phase 1b Combination Data for ORIC-944, Operational Highlights for 2024, and Anticipated Upcoming Milestones

Jan 6, 2025, 4:15 PM EST - 1 year ago

ORIC® Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Jan 3, 2025, 4:30 PM EST - 1 year ago

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Nov 1, 2024, 4:30 PM EDT - 1 year ago

ORIC® Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Oct 9, 2024, 4:15 PM EDT - 1 year ago

ORIC® Pharmaceuticals Announces Presentation at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

Aug 26, 2024, 4:05 PM EDT - 1 year ago

ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences

Aug 12, 2024, 4:05 PM EDT - 1 year ago

ORIC Pharmaceuticals Reports Second Quarter 2024 Financial Results and Operational Updates

Aug 5, 2024, 4:15 PM EDT - 1 year ago

ORIC Pharmaceuticals Expands Leadership Team with the Appointment of Keith Lui as Senior Vice President of Commercial and Medical Affairs

Jul 17, 2024, 1:00 PM EDT - 1 year ago

ORIC Pharma: ORIC-114 Advancement To Phase 1b Expansion Study Could Yield Value

Jul 16, 2024, 4:59 PM EDT - 1 year ago

ORIC Pharmaceuticals Announces Multiple Clinical Collaborations with Strategic Partners to Support Ongoing Trial Evaluating ORIC-944 in Combination with AR Inhibitors for the Treatment of Prostate Cancer

May 6, 2024, 4:05 PM EDT - 1 year ago

ORIC Pharmaceuticals Reports First Quarter 2024 Financial Results and Operational Updates

Apr 15, 2024, 4:15 PM EDT - 1 year ago

ORIC Pharmaceuticals Announces First Patients Dosed Across Three Expansion Cohorts in Phase 1b Trial of ORIC-114 in Patients with Mutated NSCLC

Apr 8, 2024, 8:00 AM EDT - 1 year ago

ORIC Pharmaceuticals Presents Preclinical Data on Two Programs at the 2024 American Association for Cancer Research (AACR) Annual Meeting

Mar 13, 2024, 8:19 AM EDT - 1 year ago

ORIC Pharmaceuticals: Mid-2024 Prostate Cancer Program Update Could Lead To Gains

Mar 11, 2024, 4:05 PM EDT - 1 year ago

ORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Updates

Mar 6, 2024, 4:30 PM EST - 1 year ago

ORIC Pharmaceuticals to Present at the Leerink Partners Global Biopharma Conference

Mar 5, 2024, 4:30 PM EST - 1 year ago

ORIC Pharmaceuticals Announces Multiple Presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting

Feb 14, 2024, 4:30 PM EST - 2 years ago

ORIC Pharmaceuticals to Participate in the Citi 2024 Virtual Oncology Leadership Summit

Jan 22, 2024, 8:30 AM EST - 2 years ago

ORIC Pharmaceuticals Announces $125 Million Private Placement Financing

Jan 8, 2024, 8:30 AM EST - 2 years ago

ORIC Pharmaceuticals Provides Initial Phase 1b Data for ORIC-944, Operational Highlights for 2023, and Anticipated Upcoming Milestones

Jan 2, 2024, 4:30 PM EST - 2 years ago

ORIC Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference

$Initial Phase 1 Dose Escalation Data for ORIC-533 in Relapsed/Refractory Multiple Myeloma Demonstrates Clinical Activity and Strong Safety Profile Supporting Potential for Combination Development$

Dec 11, 2023, 12:00 PM EST - 2 years ago

Initial Phase 1 Dose Escalation Data for ORIC-533 in Relapsed/Refractory Multiple Myeloma Demonstrates Clinical Activity and Strong Safety Profile Supporting Potential for Combination Development

Dec 9, 2023, 8:00 AM EST - 2 years ago

ORIC Pharma NSCLC Brain Metastasis Data Is Highly Interesting

CH_Expat Dec. 18 at 8:28 PM

$ORIC Interesting bloodbath here. At COGT I made a mistake and thought there were "reasons" when it traded at 200m EV. So worth watching.

1 · Reply

UgoGreg Dec. 17 at 6:38 AM

$ORIC https://youtu.be/ygBN8MilTyc

0 · Reply

McMillion1 Dec. 11 at 2:57 AM

$FDMT $GOSS $ORIC

0 · Reply

McMillion1 Dec. 10 at 12:36 PM

$ORIC $GOSS $FDMT - 12 to 24 months

0 · Reply

CH_Expat Dec. 8 at 5:17 PM

$ORIC What do you think of it at this levels?

1 · Reply

JarvisFlow Dec. 8 at 2:50 PM

Wells Fargo updates rating for ORIC Pharmaceuticals ( $ORIC ) to Overweight, target set at 19 → 25.

0 · Reply

JarvisFlow Dec. 8 at 2:39 PM

Wedbush updates rating for ORIC Pharmaceuticals ( $ORIC ) to Outperform, target set at 20.

0 · Reply

AlertsAndNews Dec. 6 at 9:49 PM

0 · Reply

OpenOutcrier Dec. 5 at 1:42 PM

$ORIC (+1.6% pre) ORIC Pharmaceuticals reports 35% response rate for lung cancer drug https://ooc.bz/l/86421

0 · Reply

Trader1141 Dec. 5 at 12:09 PM

$ORIC Short Float over 30%…. If it starts moving 😍

0 · Reply

AlertsAndNews Dec. 5 at 3:49 AM

$ORIC news after the AH close ORIC® Pharmaceuticals Presents Potential Best-in-Class Profile for Enozertinib with Robust Systemic and CNS Activity in 1L and Previously Treated NSCLC Patients with EGFR Atypical Mutations at the ESMO Asia Congress 2025

0 · Reply

YouVSYou Dec. 5 at 3:41 AM

Potential Swing Watchlist $BKKT $ORIC $UAMY $NAGE $TLRY

0 · Reply

Quantumup Dec. 4 at 4:55 PM

Goldman Sachs🏁 $ORIC at an Early-Stage Biotech Designation. $PFE $JNJ $TAK $OTSKY CGEM Here's what Goldman Sachs said in its note: https://x.com/Quantumup1/status/1996623081482162218?s=20

0 · Reply

EMbull Dec. 3 at 1:04 PM

$ORIC just another insider info from a n=1 study lol, my mom is now 1 year out from diagnosis with NSCLC exon 20 mutation with 19 brain mets, 5 bony mets, 8 liver mets all present at time of ORIC-114 initiation with no new mets and all arr stable or shrining with ORIC-114 ONLY (single therapy). I have no idea how trial is going but from this case study the drug has been magic and insane tbh. I did not expect her to be around for another christmas. All with a couple pills taken at home once a day with no symptoms. could def be a game changer. merry xmas

0 · Reply

Rounderssss4 Dec. 1 at 10:51 PM

$JANX 😬 move your money to $ORIC

1 · Reply

BEATOFtheMARKET Nov. 23 at 3:43 PM

$OPEX $OPRX $ORA 🔥 $ORCX $ORIC

0 · Reply

Quantumup Nov. 20 at 1:40 PM

Evercore ISI🏁 $ORIC Outperform/$25 $PFE $BAYRY - $ORINY $JNJ Evercore ISI in its initiation report said:

0 · Reply

JarvisFlow Nov. 20 at 12:32 PM

Evercore ISI Group updates rating for ORIC Pharmaceuticals ( $ORIC ) to Outperform, target set at 25.

0 · Reply

JarvisFlow Nov. 18 at 5:24 PM

Wolfe Research has updated their rating for ORIC Pharmaceuticals ( $ORIC ) to Peer Perform.

0 · Reply

JarvisFlow Nov. 18 at 3:42 PM

JP Morgan updates rating for ORIC Pharmaceuticals ( $ORIC ) to Overweight, target set at 17 → 20.

0 · Reply

anachartanalyst Nov. 17 at 4:05 PM

$ORIC https://anachart.com/wp-content/uploads/ana_temp/1763395479_soc-img.jpg

0 · Reply

DARKP00L Nov. 17 at 3:25 PM

$ORIC 10:14 on Nov. 17 2025 Citigroup Maintains Buy on ORIC Pharmaceuticals, Raises Price Target to $16 #tradeideas

0 · Reply

Market Cap	805.41M
Revenue (ttm)	0.00
Net Income (ttm)	-127.85M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	587,700
Avg Vol	1,306,130
Day's Range	N/A - N/A
Shares Out	97.39M
Stochastic %K	26%
Beta	1.32
Analysts	Strong Sell
Price Target	$20.83